Skip to main content

Table 2 Clinical data of the B-ALL patients

From: Overexpression of MALT1-A20-NF-κB in adult B-cell acute lymphoblastic leukemia

No.

Clinical stage

Sex

Age

WBC (×109/L)

Blast cells (%)

Hb

Platelets (×109/L)

C1

De novo

M

31

3.49

94

111

10

C2

De novo

M

71

7.99

17.3

83

118

C3

De novo

M

28

41.9

91.9

104

15

C4

De novo

M

31

7.68

71

110

28

C5

De novo

F

16

62.3

95

76

24

C6

De novo

M

16

144.7

63

68

76

C7

De novo

F

72

17.44

82

93

20

C8

De novo

F

18

33.92

60

58

4

C9

De novo

F

17

2.5

59

106

29

C10

De novo

M

38

29.54

82

53

41

C11

De novo

F

20

4.5

86

57

8

C12

De novo

M

26

27.5

88

49

24

C13

Refractory/relapse

M

26

13.3

41

113

69

C14

Refractory/relapse

F

16

18.68

33.8

98

93

C15

Refractory/relapse

F

47

10.57

82.5

86

15

C16

Refractory/relapse

M

40

4.75

41.5

79

74

C17

Refractory/relapse

F

31

11.2

3.5

105

110

C18

Refractory/relapse

F

30

61.6

54.5

108

197

C19

Refractory/relapse

M

17

3.84

57

121

39

C20

Refractory/relapse

F

59

2.48

18

81

28

  1. C1 to C20 B-ALL case 1 to 20, M male, F female, WBC white blood cell, Hb hematoglobin.